Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Public ClinicalTrials.gov record NCT06047379. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.
Study identification
- NCT ID
- NCT06047379
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Neonc Technologies, Inc.
- Industry
- Enrollment
- 134 participants
Conditions and interventions
Conditions
- Brain Metastases, Adult
- Cervical Cancer
- Colorectal Cancer
- Diffuse Astrocytoma, IDH-Mutant
- Esophageal Cancer
- Esophageal Squamous Cell Carcinoma
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Glioblastoma, IDH-wildtype
- Head and Neck Squamous Cell Carcinoma
- Melanoma
- Merkel Cell Carcinoma
- Microsatellite Instability-High Colorectal Cancer
- Microsatellite Instability-High Solid Malignant Tumor
- Mismatch Repair Deficient Colorectal Cancer
- Mismatch Repair Deficient Solid Malignant Tumor
- Non-small Cell Lung Cancer
- Renal Cell Carcinoma
- Small Cell Lung Cancer
- Squamous Cell Carcinoma
- Urothelial Carcinoma
Interventions
- Bevacizumab Drug
- Carboplatin Drug
- FOLFIRI Protocol Drug
- Ipilimumab Drug
- NEO212 Oral Capsule Drug
- Nivolumab Drug
- Paclitaxel Drug
- Pembrolizumab Drug
- Regorafenib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2023
- Primary completion
- Feb 27, 2027
- Completion
- Aug 30, 2027
- Last update posted
- Mar 1, 2026
2023 – 2027
United States locations
- U.S. sites
- 6
- U.S. states
- 4
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Precision NextGen Oncology | Beverly Hills | California | 90212 | Recruiting |
| OPN Healthcare, Inc | Glendale | California | 91203 | Recruiting |
| University of Southern California | Los Angeles | California | 90033 | Recruiting |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | Recruiting |
| Baylor, Scott and White Research Institute | Dallas | Texas | 75246 | Recruiting |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06047379, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 1, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06047379 live on ClinicalTrials.gov.